The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Health and Economic Outcomes of Vancomycin-Resistant Enterococci
Abstract
BACKGROUND: The health and economic impact of vancomycin-resistant enterococci has not been quantified. METHODS: A retrospective matched cohort study was conducted comparing the outcomes of patients with vancomycin-resistant enterococci (cases) with those of control subjects matched for length of hospital stay until inclusion in the cohort, hospital location, and calendar date. The propensity to be a vancomycin-resistant enterococci case was modeled based on patient characteristics, and included in multivariable models to adjust for confounding. Analyses included the following: (1) conditional logistic regression for mortality, surgery, intensive care unit admission, and discharge to long-term care; (2) linear regression for the logarithm of cost; and (3) accelerated failure time model for length of stay. RESULTS: A total of 233 cases were compared with 647 controls. Groups were similar in age (mean, 62 years), sex (female, 47%), and length of stay before inclusion in the cohort (mean, 8.1 days), but differed in primary diagnosis and comorbidities, past infection or colonization with methicillin sodium-resistant Staphylococcus aureus or Clostridium difficile, and treatment with cephalosporins or metronidazole. These variables were included in the propensity score, which had good to excellent prediction. Outcomes for cases vs controls and adjusted risks (relative risks [RRs]) were as follows: (1) case fatality rate, 17% vs 6% (RR, 2.13; P =.04); (2) length of stay after inclusion in the cohort, 15.1 vs 8.5 days (RR, 1.73; P<.001); (3) hospital costs, $52 449 vs $31 915 (RR, 1.40; P<.001); (4) surgery after inclusion in the cohort, 18% vs 10% (RR, 2.74; P =.001); (5) intensive care unit admission after inclusion in the cohort, 25% vs 14% (RR, 3.47; P<.001); and (6) transfer to an institution, 51% vs 35% (RR, 2.01; P =.001). CONCLUSION: Compared with a matched hospital population, a population with vancomycin-resistant enterococci was associated with severe adverse outcomes: increased mortality, morbidity, and costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maximum likelihood estimation of the attributable fraction from logistic models.
Greenland, S., & Drescher, K. (1993) · Biometrics · doi:10.2307/2532206 · Cited by 565
Cited by
Management of multidrug-resistant organisms in health care settings, 2006
Siegel, J. D., Rhinehart, E., Jackson, M., & Chiarello, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.10.006 · Cited by 1,283
Cosgrove, S. E. (2006) · Clinical Infectious Diseases · doi:10.1086/499406 · Cited by 1,271
Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G. (2006) · Clinical Infectious Diseases · doi:10.1086/499819 · Cited by 1,104
Antimicrobial resistance in developing countries. Part I: recent trends and current status
Okeke, I. N., Laxminarayan, R., Bhutta, Z. A., Duse, A. G., Jenkins, P., O'Brien, T. F., Pablos-Mendez, A., & Klugman, K. P. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70189-4 · Cited by 851
Roberts, R. R., Hota, B., Ahmad, I., Scott II, R. D., Foster, S. D., Abbasi, F., Schabowski, S., Kampe, L. M., Ciavarella, G. G., Supino, M., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/605630 · Cited by 705
Metadata
- Authors
- Carmeli, Y., Eliopoulos, G., Mozaffari, E., & Samore, M.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2002-10-28
- Volume
- 162
- Issue
- 19
- Pages
- 2223
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2102963376
- Cited by
- 249
- References
- 1
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Health and Economic Outcomes of Vancomycin-Resistant Enterococci. https://app.cochat.ai/papers/10.1001/archinte.162.19.2223
- The paper
- Carmeli, Y., Eliopoulos, G., Mozaffari, E., & Samore, M. (2002). Health and Economic Outcomes of Vancomycin-Resistant Enterococci. Archives of Internal Medicine. https://doi.org/10.1001/archinte.162.19.2223
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.